Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Isotretinoin
Drug ID BADD_D01213
Description Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued.[L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States.[L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Indications and Usage Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.[Label,L6579]
Marketing Status approved
ATC Code D10AD04; D10BA01
DrugBank ID DB00982
KEGG ID D00348
MeSH ID D015474
PubChem ID 5282379
TTD Drug ID D00DKK
NDC Product Code 10631-133; 65655-0006; 0245-0573; 61748-303; 61748-304; 72143-252; 0832-8304; 65655-0003; 65977-0135; 55111-136; 61748-302; 69238-1176; 0591-2435; 72143-232; 10631-116; 10631-118; 57664-023; 68308-573; 0555-1056; 72143-253; 57664-020; 10631-003; 10631-005; 64566-0003; 0378-6614; 68308-570; 69238-1175; 0591-2434; 0591-2501; 72143-233; 0832-8302; 10631-007; 10631-117; 57664-025; 0378-6611; 68308-571; 69238-1017; 72143-251; 72143-254; 64566-0004; 65655-0005; 0245-0570; 61748-301; 68308-575; 0555-1057; 0591-2433; 0591-2436; 10631-002; 10631-115; 10631-134; 64566-0014; 65655-0004; 76055-0010; 0245-0575; 0378-6612; 0555-1055; 72143-231; 0832-8303; 17337-0024; 55111-113; 69238-1174; 0591-2451; 72143-234; 0832-8301; 55111-137; 57664-022; 0555-1054; 67262-0003; 71052-426; 0245-0571; 55111-135; 57664-021; 57664-024
UNII EH28UP18IF
Synonyms Isotretinoin | 13-cis-Retinoic Acid | 13 cis Retinoic Acid | Isotretinoin Zinc Salt, 13-cis-Isomer | Isotretinoin Zinc Salt, 13 cis Isomer | Roaccutane | Accutane | Ro 4-3780 | Ro 4 3780 | Ro 43780
Chemical Information
Molecular Formula C20H28O2
CAS Registry Number 4759-48-2
SMILES CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oesophagitis07.08.05.0010.001286%
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.0020.001261%Not Available
Oral pain07.05.05.034--
Osteoarthritis15.01.04.0010.004503%Not Available
Osteonecrosis24.04.05.004; 15.02.04.0070.001158%
Osteoporosis15.02.03.002; 14.04.04.0020.004297%
Ovarian cyst21.11.01.002; 16.04.03.0010.003113%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pain of skin23.03.03.0030.001698%
Palpitations02.11.04.012--
Pancreatitis07.18.01.0010.005455%
Pancreatitis acute07.18.01.002--Not Available
Pancreatitis chronic07.18.01.0070.000386%Not Available
Panic attack19.06.04.0010.018551%Not Available
Panic disorder19.06.04.0020.000901%Not Available
Panic reaction19.06.04.0030.000257%Not Available
Papilloedema24.03.07.001; 17.07.02.004; 06.09.02.0020.000901%
Papule23.03.03.038--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Paranoia19.05.01.005--Not Available
Paronychia23.11.04.006; 11.02.01.054--
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.006--Not Available
Peptic ulcer07.04.07.0010.001544%Not Available
Pericarditis02.06.02.001--
Periorbital oedema06.08.03.017; 23.04.01.002; 10.01.05.010--
Personality change19.05.01.006; 17.02.05.0190.002804%
Photophobia17.17.02.006; 06.01.01.0040.004708%
Photopsia17.17.01.006; 06.02.06.004--
Photosensitivity reaction23.03.09.0030.019297%
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene